Welcome to Iris Biotech
For better service please confirm your country and language we detected.
For better service please confirm your country and language we detected.
Thank you very much for your interest in our products. All prices listed on our website are ex-works, Germany, and may attract customs duties when imported.
You may/will be contacted by the shipping company for additional documentation that may be required by the US Customs for clearance.
We offer you the convenience of buying through a local partner, Peptide Solutions LLC who can import the shipment as well as prepay the customs duties and brokerage on your behalf and provide the convenience of a domestic sale.
Continue to Iris Biotech GmbHSend request to US distributorPublished on 09/02/2017
Phase-transfer alkylations e.g. with the chiral Maruoka catalyst result in unique α-mono substituted and α,α-disubstituted unnatural amino acids. Typically such building blocks implemented in peptides increase the chemical and metabolic stability of their peptides and restrict the conformational freedom of side chains in amino acids.
Though rather costly in gram scale synthesis, this process opens new avenues for designing and economic production of appropriate building blocks in multi-kg and bulk scale. Conventional amino acids can be produced via such stereoselective alkylation of glycine or alanine without any use of metal, hence a safe and environmentally friendly technology.
References: Tanaka, M. Chem. Pharm. Bull. 2007; 55: 349-358. Maruoka M. et al; J. Am. Chem. Soc. 2003; 125: 5139-5151. Maruoka M. et al; Tetrahedron Lett. 2000; 41: 8339-8342. Maruoka M. et al; Synthesis 2001; 1716-17148. Maruoka M. et al; Process Research & Development 2008; 12: 679-687. Patents: USP (6,340,753; 6,441,231; 7,928,224; 8,252,952) JP (4,217,085; 4,502,293; 4,605,606; 5,106,562; 5,108,777; 5,108,888) SG 139,249; IN 252,017; CN ZL200680027800.6